跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
维葡瑞 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Velaglucerase Alfa for Injection
Approved
生物制品
Velaglucerase Alfa for Injection
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
🇨🇳 National Medical Products Administration
Approval Date
Feb 9, 2026
Approval ID
887PQk7eVDC
Company
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
Type
生物制品
Approval Details
Approval Id
887PQk7eVDC
Approval Number
国药准字SJ20210013
Generic Name
注射用维拉苷酶α
Generic Name En
Velaglucerase Alfa for Injection
Trade Name
维葡瑞
Drug Type
生物制品
Dosage Form
注射剂
Strength
目标装量为4.4ml,每瓶的总含量为11mg或440U维拉苷酶α。用4.3ml无菌注射用水复溶后,每瓶将提供4.0ml可抽取体积,其中含有10mg或400U维拉苷酶α。
Reg Date
2026-02-09
Expired Date
2031-02-08
Company Name
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
Company Detail Path
/organization/takeda-pharmaceuticals-international-ag-ireland-branch
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Feb 9, 2026
Approval ID
887PQk7eVDC
Type
生物制品
Back to NMPA Approvals